Table 2.
The assessment of therapeutic efficiency by TrxR, AFP, CA19-9, and CEA and their combinations after chemotherapy in PLC patients.
| Tumor markers | PLCs after chemotherapy | ||||||
|---|---|---|---|---|---|---|---|
| AUC (95%CI) | SEN% | SPE% | PPV% | NPV% | PLR | NLR | |
| Primary carcinoma of liver: CUPs vs.CRPs | |||||||
| TrxR | 0.776 (0.687–0.865) | 73.47 | 80.00 | 78.60 | 75.10 | 3.67 | 3.02 |
| AFP | 0.624 (0.529–0.718) | 75.51 | 47.37 | 58.93 | 65.92 | 1.43 | 1.93 |
| CEA | 0.588 (0.485–0.691) | 36.73 | 87.37 | 74.41 | 58.00 | 2.91 | 1.38 |
| CA19-9 | 0.433 (0.333–0.534) | 22.45 | 82.11 | 55.64 | 51.43 | 1.25 | 1.06 |
| CEA + CA19-9 + AFP | 0.574 (0.466–0.681) | 44.90 | 80.00 | 69.18 | 59.21 | 2.24 | 1.45 |
| CEA + CA19-9 + AFP + TrxR | 0.781 (0.693–0.869) | 75.51 | 78.95 | 78.20 | 76.32 | 3.59 | 3.22 |
SPE: specificity; SEN: sensitivity; NPV: negative predictive value; PPV: positive predictive value;NLR: negative likelihood ratio. PLR: positive likelihood ratio; the diagnosic threshold of TrxR activity level was 7.45 U/mL in PLC patients.